CDD-2103: Chinese Herbal Medicine for maintaining Ulcerative Colitis remission
Overview
CDD-2103 is indicated for patients in the remission phase of ulcerative colitis, primarily characterized by spleen deficiency and dysfunction, accompanied by damp-heat. The research team received approval for clinical trials from the National Medical Products Administration in China, in late August 2024.
Problem addressed
Ulcerative colitis is a relapsing-remitting chronic disease. CDD has developed CDD-2103 to help maintain or prolong remission state and reduce chance of relapse in Ulcerative colitis patients.
Innovation
- CDD-2103 is indicated for patients in the remission phase of ulcerative colitis, primarily characterized by spleen deficiency and dysfunction, accompanied by damp-heat.
- CDD-2103 has a promising effect in maintaining Ulcerative colitis remission, while show no obvious toxicity.
- Multiple components in CDD-2103 demonstrate gut barrier protection and immune regulatory functions.
Key impact
- Low cost, convenient for clinical use
- Good safety and efficacy.
Award
- Second prize in the 4th Traditional Chinese Medicine Innovation and Entrepreneurship Competition
- Gold Medal with Congratulation Jury Award, the 50th International Exhibition of Inventions Geneva
Application
- Chinese medicine granules for oral use
- Category 1.1 new drugs by NMPA China
- Proprietary Chinese Medicine Drug by Chinese medicine Council of HKSAR
Patent
- China patent: CN113827682A
- China patent: CN116712444A
- China patent: 202511085787.0
- US patent: 19/553,657
Funded by Innovation and Technology Commission (ITC) of the Hong Kong Government, Centre for Chinese Herbal Medicine Drug Development Limited (the Centre) was established in September 2020, to accelerate the development of Chinese Herbal Medicine (CHM)-based drugs, and serve as a strategic platform to promote collaborations among local and international researchers, institutions and industry. The Centre aims to achieve the goal by enhancing the quality of pre-clinical and clinical CHM research and transforming the results into pharmaceutical products for international markets. In particular, the Centre develops treatments and cures for diseases such as ulcerative colitis and chronic constipation. It also supports the incubation of new CHM-based pharmaceutical start-ups that will target the global market, and nurtures talent for CHM research in Hong Kong.
Enquiry
